Literature DB >> 26924463

Adjuvant role of radiation therapy for locally advanced laryngeal cancer without pathological lymph node metastasis.

Sung Hee Kim1, Yoon Se Lee1, Minsu Kwon1, Ji Won Kim1, Jong-Lyel Roh1, Seung-Ho Choi1, Sang Yoon Kim1, Sang-Wook Lee2, Soon Yuhl Nam1.   

Abstract

Conclusion The application of adjuvant RT to reduce recurrence should be tailored in cases of pathologically negative node metastasis. Objectives The treatment modality following surgical resection of advanced laryngeal cancer is determined by adverse factors. Aside from lymph node metastasis (LNM) or positive margins, definite risk factors supporting adjuvant radiation therapy (RT) have not been clearly suggested. The aim of this study was to analyze the risk factors for advanced laryngeal cancer without LNM and the role of RT. Materials and methods Pathologically T3 and T4-staged laryngeal squamous cell carcinoma without LNM were reviewed. The patients were classified into RT (+) (n = 22) and RT (-) (n = 38) groups. Results Five-year overall survival (OS) of the RT (+) and RT (-) groups was 84.4% and 83.8%, respectively. Five-year disease-specific survival of the RT (+) and RT (-) groups was 88.4% and 93.9%. Five-year local control rate of the RT (+) and RT (-) groups was 94.7% and 91.3%. The factors affecting OS were smoking history and recurrence history (p = 0.02). By multivariate analysis, smoking history and recurrence history were determining factors for 5-year OS (p = 0.024 and p = 0.047, respectively).

Entities:  

Keywords:  Advanced larynx cancer; head and neck cancer; lymph node metastasis; radiation therapy; treatment outcome

Mesh:

Year:  2016        PMID: 26924463     DOI: 10.3109/00016489.2016.1146827

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  1 in total

1.  A potential panel of two-long non-coding RNA signature to predict recurrence of patients with laryngeal cancer.

Authors:  Zhigang Bai; Enhong Shi; Qiwei Wang; Zhouwei Dong; Ping Xu
Journal:  Oncotarget       Date:  2017-06-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.